Purpose: To compare contrast enhanced MRI and PET-CT in the staging of multiple myeloma (MM). Methods & Materials: We evaluated 58 patients at MM diagnosis, submitted to FDG PET-CT and contrast enhanced MRI (spine and pelvis). PET-CT was performed within 15 days of MRI. Two experts 882 Skeletal Radiol (2012) 41:871–886 oncologic radiologists evaluated all the images and staged patients (according to Durie-Salmon plus staging systems) using PET-CT and MRI results separately. Results: Differences between the two imaging techniques determined staging changes in 13 patients (13/58–22.4 %): PET-CT down-staged 12 of them (12/13–92.3 %) while MRI only 1 (1/13–7.7 %). PET-CT was able to detect lesions out of MRI field of view in 6 subjects (6/58– 10.3 %). PET-CT was negative in 8 patients (8/58–13.8 %) in which MRI showed diffuse spine involvement (5/8–62.5 %) or salt-andpepper appearance (3/8–37.5 %). Conclusion: Contrast enhanced MRI is highly recommended to stage MM. PET-CT may offer important advantages for the assessment of the disease but could down-stage patients when performed alone.
P. Spinnato, A. Bazzocchi, S. Brocchi, D. Diano, F. Ponti, Salizzoni E. (2012). Differences between FDG PET-TC and contrast enhanced MRI in the staging of patients affected by multiple myeloma..
Differences between FDG PET-TC and contrast enhanced MRI in the staging of patients affected by multiple myeloma.
SPINNATO, PAOLO;BAZZOCCHI, ALBERTO;BROCCHI, STEFANO;DIANO, DANILA;PONTI, FEDERICO;SALIZZONI, EUGENIO
2012
Abstract
Purpose: To compare contrast enhanced MRI and PET-CT in the staging of multiple myeloma (MM). Methods & Materials: We evaluated 58 patients at MM diagnosis, submitted to FDG PET-CT and contrast enhanced MRI (spine and pelvis). PET-CT was performed within 15 days of MRI. Two experts 882 Skeletal Radiol (2012) 41:871–886 oncologic radiologists evaluated all the images and staged patients (according to Durie-Salmon plus staging systems) using PET-CT and MRI results separately. Results: Differences between the two imaging techniques determined staging changes in 13 patients (13/58–22.4 %): PET-CT down-staged 12 of them (12/13–92.3 %) while MRI only 1 (1/13–7.7 %). PET-CT was able to detect lesions out of MRI field of view in 6 subjects (6/58– 10.3 %). PET-CT was negative in 8 patients (8/58–13.8 %) in which MRI showed diffuse spine involvement (5/8–62.5 %) or salt-andpepper appearance (3/8–37.5 %). Conclusion: Contrast enhanced MRI is highly recommended to stage MM. PET-CT may offer important advantages for the assessment of the disease but could down-stage patients when performed alone.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
